Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Cdymax (India) Pharma Private Limited
WARNING LETTER
•Cdymax (India) Pharma Private Limited•April 25, 2025

Cdymax (India) Pharma Private Limited – FDA Warning Letter, Apr 25, 2025

Record Details

The U.S. Food and Drug Administration (FDA) issued a Warning Letter to Cdymax India Pharma Private Limited following an inspection of its Bangalore, Karnataka, facility from April 21 to 25, 2025. The letter highlights significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs), leading to the APIs being deemed adulterated under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act. The primary violation was the company"s failure to adequately investigate and document out-of-specification (OOS) results and implement appropriate corrective actions. The FDA noted approximately 1,500 laboratory incidents since 2023 involving OOS results and other significant analytical events, many with inadequate root cause analysis and corrective/preventive actions (CAPAs). Investigations frequently failed to classify incidents as OOS results, and manufacturing investigations were often omitted when laboratory root causes were not definitive. An example cited involved an OOS result for an "unknown peak" in a stability sample, where retesting and invalidation occurred without a thorough scientific root cause analysis. The FDA deemed the company"s response inadequate, citing inconsistencies and lack of evidence for systemic remediation. Cdymax India Pharma Private Limited is required to conduct comprehensive, independent assessments of its overall investigation and CAPA programs, including a retrospective review of all laboratory incidents and OOS results for U.S. products over the last four years. These actions must ensure effective root cause analysis, improve quality unit oversight, and implement robust corrective measures to prevent recurrence.

Company
Cdymax (India) Pharma Private Limited
Inspection date
April 25, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 5483d583-5418-4d4b-8801-ace48e9e8d53

Violation Codes5
21 U.S.C. 351(a)(2)(B)FD&C Act 501(a)(2)(B)21 U.S.C. 356c(a)FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)

Full citation text and observation details available on the Dashboard.

Other documents for Cdymax (India) Pharma Private Limited
  • 483 - 2025-04-25April 25, 2025
  • 483 - 2019-05-17May 17, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Cdymax (India) Pharma Private Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.